MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC
Sign Up to like & getrecommendations! Published in 2017 at "Virchows Archiv"
DOI: 10.1007/s00428-017-2131-1
Abstract: The prevalence of overexpression and amplification of the proto-oncogene mesenchymal epithelial transition (MET) in non-small cell lung cancer (NSCLC) varies greatly in the literature. Since MET is a potential treatment target, knowledge of its prevalence… read more here.
Keywords: overexpression; met overexpression; prevalence; gene ... See more keywords
Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Cancer"
DOI: 10.1038/s41416-021-01334-9
Abstract: Background This Phase 1b/2 study evaluated tepotinib, a highly selective MET inhibitor, in US/European patients with sorafenib pretreated advanced hepatocellular carcinoma (aHCC) with MET overexpression. Methods Eligible adults had aHCC, progression after ≥4 weeks of… read more here.
Keywords: phase; met overexpression; sorafenib pretreated; advanced hepatocellular ... See more keywords
MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas
Sign Up to like & getrecommendations! Published in 2021 at "Journal for ImmunoTherapy of Cancer"
DOI: 10.1136/jitc-2021-002451
Abstract: Background Dysregulated receptor tyrosine kinases, such as the mesenchymal-epidermal transition factor (MET), have pivotal role in gliomas. MET and its interaction with the tumor microenvironment have been previously implicated in secondary gliomas. However, the contribution… read more here.
Keywords: glioma; tumor associated; analysis; met overexpression ... See more keywords
Abstract 3815: The clinical impact of c-MET over-expression in advanced biliary tract cancers
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-3815
Abstract: Background: c-MET is a proto-oncogene that encodes the tyrosine kinase receptor for hepatocyte growth factor (HGF). Activation of HGF-c-MET signaling involves cell invasiveness and evokes metastasis through direct involvement of tumor angiogenesis. However, the value… read more here.
Keywords: overexpression; met expression; met overexpression; significant difference ... See more keywords
Abstract 1069: A novel PAThway based RNA and DNA Integration with Tumor Organoid Testing (PATRIOTTM) platform predicts therapeutic options in cohorts with MET overexpression and CDKN2A downregulation in patients with colon and pancreatic cancers
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-1069
Abstract: Background: Cancer therapy has witnessed great progress over the last 50 years with advancements in diagnostic tools to enable more precise treatment. With the development of next-generation sequencing, the field of precision oncology has been… read more here.
Keywords: platform; met overexpression; downregulation; tumor ... See more keywords
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
Sign Up to like & getrecommendations! Published in 2018 at "BMC Cancer"
DOI: 10.1186/s12885-018-5078-y
Abstract: ObjectiveCrizotinib can target against mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK), which has been considered as a multi-targeted tyrosine kinase inhibitor (TKI). The objective of this study was to explore the efficacy of crizotinib… read more here.
Keywords: overexpression; alk rearrangement; met overexpression; cancer ... See more keywords